Security
Travere Therapeutics, Inc. Common Stock · TVTX
TVTXNASDAQCommon stockCurrentCIK 1438533Updated Nov 17, 2026
TVTX price & chart
Loading TradingView…
NASDAQ:TVTX on TradingView ↗About the company
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent - that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow. For more information, visit travere.com.
In the news
Seeking Alpha
Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript ↗
Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy ↗
Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy ↗
SEC disclosures
Travere Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
SCHEDULE 13G/A - filed by BANK OF AMERICA CORP /DE/ regarding Travere Therapeutics, Inc.
SCHEDULE 13G/A - filed by FMR LLC regarding Travere Therapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 538,581,000Source | 504,410,000Source | 799,360,000Source | 555,309,000Source | 551,121,000Source | 555,188,000Source | 548,799,000Source | 663,547,000Source | 605,191,000Source | 594,125,000Source | 788,913,000Source | 672,585,000Source |
| Property, Plant and Equipment, NetUSD | 4,320,000Source | 6,162,000Source | 3,231,000Source | 4,561,000Source | 6,580,000Source | 3,627,000Source | 4,853,000Source | 6,943,000Source | 4,022,000Source | 5,336,000Source | 7,479,000Source | 9,049,000Source |
| GoodwillUSD | 800,000Source | 800,000Source | — | 800,000Source | 800,000Source | — | 800,000Source | 800,000Source | — | 800,000Source | 800,000Source | 900,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 109,435,000Source | 104,205,000Source | 131,518,000Source | 105,607,000Source | 105,174,000Source | 110,038,000Source | 103,816,000Source | 101,182,000Source | 113,868,000Source | 103,974,000Source | 104,443,000Source | 145,038,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 110,930,000Source | 36,409,000Source | 117,735,000Source | 75,154,000Source | 32,291,000Source | 78,362,000Source | 61,897,000Source | 43,251,000Source | 93,035,000Source | 58,535,000Source | 58,176,000Source | 61,688,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 82,984,000Source | 25,170,000Source | 80,636,000Source | 38,718,000Source | 24,466,000Source | 87,302,000Source | 34,381,000Source | 22,731,000Source | 80,134,000Source | 27,116,000Source | 21,179,000Source | 16,646,000Source |
| Inventory, NetUSD | 37,547,000Source | 42,878,000Source | 40,049,000Source | 37,680,000Source | 42,980,000Source | 37,054,000Source | 38,005,000Source | 42,306,000Source | 36,155,000Source | 6,200,000Source | 9,410,000Source | 6,922,000Source |
| Assets, CurrentUSD | 371,110,000Source | 324,740,000Source | 615,141,000Source | 379,567,000Source | 368,977,000Source | 392,681,000Source | 374,171,000Source | 481,076,000Source | 437,565,000Source | 416,702,000Source | 616,775,000Source | 486,437,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 28,048,000Source | 15,775,000Source | 37,493,000Source | 17,222,000Source | 13,139,000Source | 34,347,000Source | 13,616,000Source | 12,769,000Source | 28,760,000Source | 12,685,000Source | 19,335,000Source | 12,624,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,464,000Source | 15,662,000Source | 8,745,000Source | 12,336,000Source | 16,467,000Source | 9,668,000Source | 13,196,000Source | 17,271,000Source | 10,576,000Source | 14,295,000Source | 18,061,000Source | 21,000,000Source |
| Other Assets, NoncurrentUSD | 10,253,000Source | 17,119,000Source | 8,511,000Source | 19,648,000Source | 16,919,000Source | 8,476,000Source | 18,690,000Source | 19,301,000Source | 8,880,000Source | 18,162,000Source | 10,661,000Source | 11,061,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 465,017,000Source | 534,864,000Source | 774,838,000Source | 522,562,000Source | 535,974,000Source | 456,460,000Source | 515,976,000Source | 589,476,000Source | 490,363,000Source | 535,048,000Source | 588,103,000Source | 629,734,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 9,000Source | 8,000Source | 9,000Source | 9,000Source | 8,000Source | 9,000Source | 9,000Source | 8,000Source | 9,000Source | 9,000Source | 7,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 1,550,051,000Source | 1,357,457,000Source | 1,570,242,000Source | 1,534,698,000Source | 1,348,865,000Source | 1,609,596,000Source | 1,522,050,000Source | 1,337,638,000Source | 1,588,721,000Source | 1,506,315,000Source | 1,327,881,000Source | 1,059,975,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,475,442,000Source | -1,386,903,000Source | -1,544,612,000Source | -1,501,148,000Source | -1,332,092,000Source | -1,509,815,000Source | -1,488,393,000Source | -1,261,683,000Source | -1,472,713,000Source | -1,447,167,000Source | -1,125,622,000Source | -1,014,223,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,054,000Source | -1,016,000Source | -1,117,000Source | -812,000Source | -1,634,000Source | -1,062,000Source | -843,000Source | -1,892,000Source | -1,189,000Source | -80,000Source | -1,456,000Source | -2,907,000Source |
| Stockholders' Equity Attributable to ParentUSD | 73,564,000Source | -30,454,000Source | 24,522,000Source | 32,747,000Source | 15,147,000Source | 98,728,000Source | 32,823,000Source | 74,071,000Source | 114,828,000Source | 59,077,000Source | 200,810,000Source | 42,851,000Source |
| Liabilities and EquityUSD | 538,581,000Source | 504,410,000Source | 799,360,000Source | 555,309,000Source | 551,121,000Source | 555,188,000Source | 548,799,000Source | 663,547,000Source | 605,191,000Source | 594,125,000Source | 788,913,000Source | 672,585,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 135,074,000Source | 190,038,000Source | 152,025,000Source | 189,540,000Source | 121,268,000Source | 125,437,000Source | 182,457,000Source | 173,229,000Source | 159,904,000Source | 200,751,000Source | 177,908,000Source | 142,163,000Source |
| Operating Lease, Liability, CurrentUSD | 5,734,000Source | 5,297,000Source | 6,163,000Source | 5,595,000Source | 5,163,000Source | 6,017,000Source | 5,460,000Source | 5,036,000Source | 5,875,000Source | 5,405,000Source | 4,909,000Source | 4,433,000Source |
| Accounts Payable, CurrentUSD | 18,225,000Source | 23,195,000Source | 7,495,000Source | 19,134,000Source | 25,843,000Source | 12,912,000Source | 15,374,000Source | 16,725,000Source | 24,800,000Source | 23,534,000Source | 41,675,000Source | 17,290,000Source |
| Operating Lease, Liability, NoncurrentUSD | 12,645,000Source | 18,581,000Source | 7,961,000Source | 14,124,000Source | 19,938,000Source | 9,566,000Source | 15,582,000Source | 21,287,000Source | 11,134,000Source | 17,191,000Source | 22,612,000Source | 27,510,000Source |
| Other Liabilities, NoncurrentUSD | 5,928,000Source | 16,288,000Source | 12,071,000Source | 7,882,000Source | 16,643,000Source | 9,378,000Source | 7,274,000Source | 16,379,000Source | 7,601,000Source | 6,796,000Source | 8,485,000Source | 9,385,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 105,762,000Source | 83,916,000Source | 136,267,000Source | 81,682,000Source | 79,641,000Source | 104,408,000Source | 77,108,000Source | 139,580,000Source | 126,035,000Source | 86,028,000Source | 118,991,000Source | 95,742,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 25,212,000Source | 12,802,000Source | 60,743,000Source | 43,555,000Source | 38,530,000Source | 33,079,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 16,146,000Source | 11,492,000Source | 44,868,000Source | 36,913,000Source | 44,246,000Source | 39,177,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 7,225,000Source | 7,204,000Source | 27,822,000Source | 6,001,000Source | 11,264,000Source | 682,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 742,000Source | -3,664,000Source | -5,016,000Source | 3,771,000Source | 39,420,000Source | 2,064,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | — | — | — | 2,307,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -40,366,000Source | -42,194,000Source | 37,784,000Source | -237,475,000Source | -280,021,000Source | -186,291,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 21,549,000Source | 41,290,000Source | 27,892,000Source | 99,325,000Source | 55,776,000Source | -32,553,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 83,000Source | 404,000Source | 40,000Source | 0Source | 600,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 668,000Source | 191,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 4,204,000Source | 3,718,000Source | -33,467,000Source | 139,422,000Source | 218,752,000Source | 117,573,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -14,673,000Source | 3,362,000Source | 34,500,000Source | 359,000Source | -3,512,000Source | -104,065,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 110,930,000Source | 36,409,000Source | 117,735,000Source | 75,154,000Source | 78,362,000Source | 61,897,000Source | 93,035,000Source | 58,535,000Source | 58,176,000Source | 61,688,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 8,838,000Source | 8,838,000Source | 8,838,000Source | 10,159,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | 453,000Source | 578,000Source | 996,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -60,000Source | 548,000Source | 2,291,000Source | -913,000Source | 1,981,000Source | -2,794,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 11,263,000Source | 8,021,000Source | 21,788,000Source | 10,649,000Source | 16,146,000Source | 11,492,000Source | 44,868,000Source | 36,913,000Source | 44,246,000Source | 39,177,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | 1,640,000Source | 1,725,000Source | 1,718,000Source | 1,622,000Source |
| Amortization of Intangible AssetsUSD | — | — | 15,400,000Source | 10,800,000Source | 3,800,000Source | 13,600,000Source | 24,800,000Source | 12,400,000Source | 59,210,000Source | 41,739,000Source | 36,282,000Source | 30,964,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 1,500,000Source | 1,800,000Source | 2,200,000Source | 2,100,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -300,000Source | -700,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | -7,578,000Source |
| GoodwillUSD | — | — | 800,000Source | 800,000Source | — | 800,000Source | — | 800,000Source | — | 800,000Source | 800,000Source | 900,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | 25,706,000Source | -54,752,000Source | -34,797,000Source | -12,755,000Source | -36,602,000Source | -41,226,000Source | -50,261,000Source | -320,630,000Source | -376,333,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | 0Source | -59,000Source | 0Source | 0Source | -500,000Source | 0Source | 24,715,000Source | -915,000Source | 264,934,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 8,000Source | -84,000Source | -204,000Source | 20,000Source | -120,000Source | 39,000Source | 988,000Source | 120,000Source | 223,000Source | 313,000Source |
| InterestExpenseNonoperatingUSD | — | — | 2,751,000Source | 2,777,000Source | 2,134,000Source | 2,846,000Source | 2,300,000Source | 2,857,000Source | 10,748,000Source | 11,182,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 684,000Source | 2,819,000Source | 3,039,000Source | 2,455,000Source |
| Investment Income, InterestUSD | — | — | 3,047,000Source | 3,570,000Source | 3,356,000Source | 3,287,000Source | 2,584,000Source | 3,795,000Source | 12,721,000Source | 17,817,000Source | 21,768,000Source | 6,276,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 25,706,000Source | -54,811,000Source | -34,797,000Source | -12,755,000Source | -37,102,000Source | -41,226,000Source | -25,546,000Source | -321,545,000Source | -111,399,000Source | -278,482,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 25,706,000Source | -54,811,000Source | -34,797,000Source | -12,755,000Source | -37,102,000Source | -41,226,000Source | -25,546,000Source | -321,545,000Source | -111,399,000Source | -278,482,000Source |
| Nonoperating Income (Expense)USD | — | — | 783,000Source | 1,313,000Source | -38,955,000Source | -85,000Source | 193,000Source | 1,487,000Source | 13,551,000Source | 3,317,000Source | 12,028,000Source | -11,603,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,100,000Source | 1,300,000Source | 1,100,000Source | 1,100,000Source | 1,100,000Source | 1,100,000Source | 4,400,000Source | 4,800,000Source | 4,900,000Source | 5,000,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 487,000Source | 520,000Source | -169,000Source | -526,000Source | -91,000Source | 549,000Source | 11,578,000Source | -3,318,000Source | 1,594,000Source | 974,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 134,738,000Source | 191,198,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 4,729,000Source | 4,243,000Source | 34,745,000Source | 4,452,000Source | 3,240,000Source | 4,585,000Source |
| Restructuring CostsUSD | — | — | — | 100,000Source | — | — | — | — | — | — | 11,400,000Source | — |
| Induced Conversion of Convertible Debt Expense | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 164,859,000Source | 62,898,000Source | 169,584,000Source | 114,449,000Source | 127,199,000Source | 81,732,000Source | 490,728,000Source | 233,175,000Source | 145,238,000Source | 212,018,000Source |
| Cost of RevenueUSD | — | — | 1,585,000Source | 1,626,000Source | 2,174,000Source | 1,521,000Source | 1,950,000Source | 4,679,000Source | 10,339,000Source | 7,744,000Source | 11,450,000Source | 7,592,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 86,453,000Source | 65,619,000Source | 96,112,000Source | 62,581,000Source | 80,254,000Source | 60,413,000Source | 337,202,000Source | 264,119,000Source | 265,542,000Source | 220,206,000Source |
| Operating Income (Loss)USD | — | — | 24,931,000Source | -56,149,000Source | 3,954,000Source | -12,650,000Source | -36,915,000Source | -42,674,000Source | -62,824,000Source | -323,827,000Source | -388,138,000Source | -266,566,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 487,000Source | 520,000Source | -169,000Source | -526,000Source | -91,000Source | 549,000Source | 11,578,000Source | -3,318,000Source | 1,594,000Source | 974,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 25,714,000Source | -54,836,000Source | -35,001,000Source | -12,735,000Source | -36,722,000Source | -41,187,000Source | -49,273,000Source | -320,510,000Source | -376,110,000Source | -278,169,000Source |
| Income Tax Expense (Benefit)USD | — | — | 8,000Source | -84,000Source | -204,000Source | 20,000Source | -120,000Source | 39,000Source | 988,000Source | 120,000Source | 223,000Source | 313,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 25,706,000Source | -54,811,000Source | -34,797,000Source | -12,755,000Source | -37,102,000Source | -41,226,000Source | -25,546,000Source | -321,545,000Source | -111,399,000Source | -278,482,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.29Source | -0.7Source | -0.37Source | -0.14Source | -0.4Source | -0.47Source | -0.29Source | -4.08Source | -1.5Source | -4.37Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.28Source | -0.7Source | -0.37Source | -0.14Source | -0.4Source | -0.47Source | -0.29Source | -4.08Source | -1.5Source | -4.37Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 89,230,420Source | 77,779,379Source | 93,479,416Source | 88,945,624Source | 91,868,862Source | 88,355,973Source | 89,211,813Source | 78,888,861Source | 74,267,418Source | 63,758,515Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 102,618,560Source | 77,779,379Source | 93,479,416Source | 88,945,624Source | 91,868,862Source | 88,355,973Source | 89,211,813Source | 78,888,861Source | 74,267,418Source | 63,758,515Source |
| Interest Expense (non-operating)USD | — | — | 2,751,000Source | 2,777,000Source | 2,134,000Source | 2,846,000Source | 2,300,000Source | 2,857,000Source | 10,748,000Source | 11,182,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 15,400,000Source | 10,800,000Source | 3,800,000Source | 13,600,000Source | 24,800,000Source | 12,400,000Source | 59,210,000Source | 41,739,000Source | 36,282,000Source | 30,964,000Source |
| Costs and ExpensesUSD | — | — | 139,928,000Source | 119,047,000Source | 165,630,000Source | 127,099,000Source | 164,114,000Source | 124,406,000Source | 553,552,000Source | 557,002,000Source | 533,376,000Source | 478,584,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 988,000Source | 120,000Source | 223,000Source | 313,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -300,000Source | -700,000Source | — | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | 25,706,000Source | -54,752,000Source | -34,797,000Source | -12,755,000Source | -36,602,000Source | -41,226,000Source | -50,261,000Source | -320,630,000Source | -376,333,000Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -0.7Source | -0.37Source | -0.14Source | -0.4Source | -0.47Source | -0.57Source | -4.07Source | -5.07Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -0.7Source | -0.37Source | -0.14Source | -0.4Source | -0.47Source | -0.57Source | -4.07Source | -5.07Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | 0Source | -59,000Source | 0Source | 0Source | -500,000Source | 0Source | 24,715,000Source | -915,000Source | 264,934,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 11,300,000Source | 11,300,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | -11,334,000Source | -11,275,000Source |
| Investment Income, InterestUSD | — | — | 3,047,000Source | 3,570,000Source | 3,356,000Source | 3,287,000Source | 2,584,000Source | 3,795,000Source | 12,721,000Source | 17,817,000Source | 21,768,000Source | 6,276,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 25,706,000Source | -54,811,000Source | -34,797,000Source | -12,755,000Source | -37,102,000Source | -41,226,000Source | -25,546,000Source | -321,545,000Source | -111,399,000Source | -278,482,000Source |
| Nonoperating Income (Expense)USD | — | — | 783,000Source | 1,313,000Source | -38,955,000Source | -85,000Source | 193,000Source | 1,487,000Source | 13,551,000Source | 3,317,000Source | 12,028,000Source | -11,603,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,100,000Source | 1,300,000Source | 1,100,000Source | 1,100,000Source | 1,100,000Source | 1,100,000Source | 4,400,000Source | 4,800,000Source | 4,900,000Source | 5,000,000Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 7,500,000Source |
| Restructuring CostsUSD | — | — | — | 100,000Source | — | — | — | — | — | — | 11,400,000Source | — |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic | — | — | — | —Source | — | — | — | — | — | — | — | — |
Filing attachments
a2026q3_8-kxex991.htm · 8-K · 2026-11-02
Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Third Quarter 2026 Financial Results U.S. net product sales of FILSPARI® totaled $200 million, representing 120% growth year-over-year; 1,932 new PSFs received during the quarter Phase 3 HARMONY Study of pegtibatinase enrollment progressing; topline results on track for the second half of 2027 Civorebrutinib U.S. IND submission…
Read attachment ↗a2026q2_8-kxex991.htm · 8-K · 2026-08-04
EX-99.1 2 a2026q2_8-kxex991.htm EX-99.1 Document Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Second Quarter 2026 Financial Results Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarter U.S. net product sales of FILSPARI grew 96% year-over-year to $141 million Enrollment of pegtibatinase Phase 3 H…
Read attachment ↗ex991_8-kx20260519eip.htm · 8-K · 2026-05-21
EX-99.1 2 ex991_8-kx20260519eip.htm EX-99.1 Document EXHIBIT 99.1 2018 Equity Incentive Plan Adopted by the Board of Directors: April 1, 2018 Approved by the Stockholders: May 9, 2018 Amended by the Board of Directors: April 1, 2019 Approved by the Stockholders: May 8, 2019 Amended by the Board of Directors: April 8, 2020 Approved by the Stockholders: May 15, 2020 Amended by the Board of Directors: April 6, 2021 Approved by the Stockholders: May 14, 2021 Amended by the Board of Di…
Read attachment ↗d38424dex41.htm · 8-K · 2026-05-11
EX-4.1 3 d38424dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 EXECUTION VERSION TRAVERE THERAPEUTICS, INC., as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 11, 2026 Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS …
Read attachment ↗d38424dex42.htm · 8-K · 2026-05-11
EX-4.2 4 d38424dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 EXECUTION VERSION TRAVERE THERAPEUTICS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 11, 2026 0.50% Convertible Senior Notes due 2032 CROSS REFERENCE TABLE* Trust Indenture Indenture Section Act Section 310(a)(1) N/A (a)(2) N/A (a)(3) N/A (a)(4) …
Read attachment ↗d38424dex991.htm · 8-K · 2026-05-11
EX-99.1 6 d38424dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes 2026-05-05 SAN DIEGO - (BUSINESWIRE) - Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 (the “Notes”) in an underwritten offering. Travere also expects to grant the underwriters of the Not…
Read attachment ↗